Kither Biotech Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$20.6M
- Investors
-
13
Kither Biotech General Information
Description
Developer of anticancer and anti-inflammation drugs intended for pulmonary diseases with unmet medical needs. The company provides services in drugs that are researched for the treatment of cystic fibrosis, a disease that predominantly affects the lungs, and is in line to create medication for the cure of chronic obstructive pulmonary diseases, allergic asthma, and idiopathic pulmonary fibrosis, enabling patients to have a treatment for their respiratory diseases.
Contact Information
Website
www.kitherbiotech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Via Nizza 52
- 10126 Turin
- Italy
Kither Biotech Timeline
Kither Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 16-Mar-2022 | $20.6M | 0000 | Completed | Pre-Clinical Trials | |
| 2. Later Stage VC (Series A) | 05-Jul-2019 | 00.000 | 00.000 | 0000 | Completed | Pre-Clinical Trials |
| 1. Accelerator/Incubator | Completed | Startup |
Kither Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
Kither Biotech Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of anticancer and anti-inflammation drugs intended for pulmonary diseases with unmet medical needs. The compan
Drug Discovery
Turin, Italy
9
As of 2022
0000
00000000000
0000
0000 0
t nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt
0000 000000000
Austin, TX
00
As of 0000
000.00
0000000000 0
000.00
000000
p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000 000000000
Marburg, Germany
0
As of 0000
000.00
00000000000
000.00
Add Comparison
Kither Biotech Competitors (24)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lung Therapeutics | Venture Capital-Backed | Austin, TX | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000000 00000000000 | Venture Capital-Backed | Marburg, Germany | 0 | 000.00 | 00000000000 | 000.00 |
| 00000 | Formerly VC-backed | Umea, Sweden | 0 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 | Venture Capital-Backed | Seattle, WA | 00 | 00000 | 000000000 | 00000 |
Kither Biotech Patents
Kither Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10730921-B2 | Pi3kγ inhibitor peptide for treatment of respiratory system diseases | Active | 24-Dec-2014 | 00000000000 | 0 |
| ES-2737227-T3 | Novel pi3k gamma inhibitor peptide for the treatment of diseases of the respiratory system | Active | 24-Dec-2014 | 00000000000 | |
| EP-3236983-B1 | Novel pi3k gamma inhibitor peptide for treatment of respiratory system diseases | Active | 24-Dec-2014 | 00000000000 | |
| US-20190367571-A1 | Novel pi3k gamma inhibitor peptide for treatment of respiratory system diseases | Granted | 24-Dec-2014 | 00000000000 | |
| US-20180086798-A1 | Novel pi3k gamma inhibitor peptide for treatment of respiratory system diseases | Granted | 24-Dec-2014 | C07K14/4703 |
Kither Biotech Executive Team (7)
Kither Biotech Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Heikki Lanckriet Ph.D | Self | Board Member | 000 0000 |
| Laura Iris Ferro | Self | Chairman | 000 0000 |
| Marco Malisani | Kither Biotech | Chief Financial Officer & Board Member | 000 0000 |
| Pietro Puglisi | Claris Ventures | Board Member | 000 0000 |
| Vincent Metzler Ph.D | Kither Biotech | Chief Executive Officer and Board Member | 000 0000 |
Kither Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kither Biotech Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 2invest | Corporation | Minority | 000 0000 | 000000 0 | |
| 3B Future Health Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Ace Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| CDP Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Claris Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |